摘要 |
<p>The deleterious symptoms of autoimmune disease in a patient suffering from symptoms of autoimmune disease can be relieved by by co-administration of a cell-mediated immune inhibiting effective amount of at least one inhibitor of dihydrofolate reductase and a folate wherein the folate is formulated for delayed release in a carrier.</p> |